top of page

Optimizing Cell Therapy to Defeat Cancer

We combine precision stem cell engineering and NK-activating antibodies to unlock the full potential of Natural Killer cells as a first line of defense against cancer.

Home: Welcome

Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2022, moving towards broad patient access to cancer-defeating cures."

Dr. Daniel Teper,

Cytovia Therapeutics CEO

Cytovia In The News

bottom of page